Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc.
Through a recent notice, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has ...
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...
Can gene editing truly support smallholder farmers and help Indonesia achieve food sovereignty, or will it simply revive the ...
Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...
Patented Green Extraction Technology Transforms Black Soldier Fly Waste Into Pure Insulin at 50% of Synthetic Insulin Cost Half-price natural Insulin is finally within reach, thanks to generational ...
Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 DIAGNODE-3 trial in type ...
A new, groundbreaking real-world evidence study in Diabetes Technology and Therapeutics analyzing 938,740 matched patients has found that continuous glucose monitor (CGM) use among individuals with ...
Managing diabetes has always been a complex task, involving careful monitoring of blood sugar levels, diet, and lifestyle. But the future promises exciting changes. By 2026, emerging technologies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback